About Us
Ixtlan Bioscience
Ixtlan Bioscience is an Israeli based biotech company devoted to defining and utilizing psilocybin micro-dosing to advance safe and accessible psilocybin medicine to slow down the progression of Alzheimer’s and dementia diseases.
With our professional team’s expertise in neuroscience and neuropsychiatry as well as background in academic research in Alzheimer and dementia, we understand failures of the healthcare system to provide at-home neurorecovery solutions, which would provide accessibility to those unable to easily commute to receive in-person therapy.
In light of this crisis, our initial focus is developing our novel and proprietary, patent pending, Ixtlan AD Kit, for the at-home treatment of patients suffering from Alzheimer’s and dementia diseases.
We at Ixtlan envision a future where everyone has the opportunity to benefit from safe and accessible psilocybin medicine and are determined to increase the access to transformative power of these compounds.
Meet the Team
Itamar Borochov
Co-founder and CEO
An environmentalist and entrepreneur in Medical Psychedelic and Medical Cannabis projects which operate in regulated markets, The Founder and former CEO of Cannabics Pharmaceuticals Inc.
PhD. Ana Parabucki
Co-founder and Chief Science
Neuroscientist and electrophysiologist. data science, machine learning, medical devices and novel treatments designed to help overcome CNS pathologies.
MD Christopher Freeman
Scientific Advisory
BOD at American Board of Mental Health Consultant. MD of public health from Tufts Uni School of Medicine, Boston. Residency in Psychiatry at Uni of Massachusetts Medical and Fellowship in Neuropsychiatry. Expertise in Alzheimer and Dementia.
Shlomo Pekar
Co-founder and COO
Professional in the Cannabis Industry and Physical Health with over 15 years of experience growing mushrooms. B.Sc Environmental Science. Shlomo is a veteran of the IDF's Special Forces.
Yehonatan Cavens
Co-founder and CFO
Former director of Novitech Education and PowerMobility. With over 10 years of experience in capital markets and practice in executing complex M&As in stock exchanges. Yehonatan is a veteran of the IDF's Special Forces.
